<h4>Background</h4>National recommendations since 2004 have allowed for omission of post-lumpectomy radiotherapy for patients ≥70 years old with early-stage estrogen receptor positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Here, ERBB2 is linked to breast carcinoma.